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Pﬁesteria piscicida Steidinger & Burkholder is
a relatively newly recognized species of toxic
estuarine dinoflagellate inhabiting east coast
waterways in the United States. This organ-
ism has been associated with numerous large
fish kills in these areas since its discovery in
1991 (1). Pfiesteria has a complicated life
cycle involving approximately two dozen
morphologically distinct life forms. Although
it is thought that at least two toxins are
released at certain stages of the life cycle, as
yet they have not been puriﬁed and character-
ized fully. These toxins result in stunning of
ﬁsh prey and are associated with rapid devel-
opment of skin lesions on the ﬁsh. However,
as yet there is no specific or even surrogate
biomarker for exposure.
In humans, known occupational and
putative civilian exposures to Pfiesteria have
been associated with memory complaints,
confusion, skin burning or rash, headaches,
eye irritation, respiratory irritation, muscle
cramps, and gastrointestinal distress (2).
Formal investigations have established an asso-
ciation between exposure to Pfiesteria and
deﬁcits in information processing. Speciﬁcally,
learning and higher cognitive function deﬁcits
were related to contact with waterways con-
taining fish exposed to toxins produced by
Pﬁesteria or Pﬁesteria-like dinoﬂagellate species
on the Pocomoke River and adjacent water-
ways in Maryland (3). Severity of illness was
related to the degree of exposure, and test
scores returned to within the normal range
after a period of exposure cessation (3). The
observed resolution of symptoms was consis-
tent with that suggested in reports of some
cases followed longitudinally at Duke
University Medical Center in Durham, North
Carolina (2). The potentially transient nature
of symptoms associated with the syndrome is
also indirectly supported by the lack of evi-
dence for marked, consistent deficits in a
North Carolina cohort studied 2–3 months
after the last recognized fish kill involving
Pﬁesteria (4). Finally, learning and processing
difficulties in rats exposed to extracts of the
Pﬁesteria toxin have also been reported (5,6),
and these effects were also thought to be dose
responsive. Overall, the present state of
knowledge suggests that exposure to P.
piscicida can result in a mild, transient
encephalopathy primarily affecting learning
and memory and higher-order executive func-
tions. However, data on the potential central
nervous system (CNS) effects of exposure is
sparse, and large epidemiological cohort
studies currently under way have been hin-
dered by the recent drop in Pﬁesteria-related
ﬁsh kills and the lack of a biomarker to assist
in case identiﬁcation. 
The index case of prolonged, intense
laboratory exposure to P. piscicida presented
to the Memory Disorders Clinic (MDC) of
the Bryan Alzheimer’s Disease Research
Center (ADRC) at Duke University Medical
Center in December 1993. This patient has
been followed since that time and is now pre-
sented in an effort to delineate some of the
potential adverse human health effects associ-
ated with exposure. To protect conﬁdential-
ity, we removed all identifying information.
The case is then discussed in the context of
other laboratory and civilian cases that have
presented to the MDC for evaluation.
Finally, the theoretical and scientific frame-
works in which Pfiesteria exposure sequelae
research progresses is considered.
Case History
The patient was a healthy, well-educated
Caucasian with no known risk factors for ill-
ness. Medical history was negative for
known or suspected illnesses affecting the
CNS. Family history was also negative for
neurological and psychiatric disorders. 
Exposure History
During 1991 and 1992, the patient had
gradually increasing research responsibilities
involving cultures of toxic forms of P. pisci-
cida. These activities involved feeding, clean-
ing, and harvesting in an enclosed room
housing aquaria with fish and Pfiesteria cul-
tures. Exposures were inhalational and dermal
in the humid atmosphere of this room and
included handling of killed and decomposing
fish resulting from cultures of the activated
forms of Pfiesteria. During this time, the
patient reportedly experienced several distinct
episodes of euphoria and disorientation.
Interestingly, there was a relative inability to
terminate exposure despite realization of these
symptoms and a sense of urgency to finish
tasks. The patient experienced relatively rapid
recovery within an hour after these events and
was able to function adequately between
episodes without major adverse effects.
During 1993 additional safety precautions
including gloves and respirator masks were
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taken because of increased culturing activity.
However, an unfortunate construction error
during expansion of the laboratory physical
layout resulted in cross-ventilation of the
aquarium heating, ventilation, and air-
conditioning to the desk area of the patient.
Exposure during this 8- to 9-month period
was reported to be daily for 8–10 hr. In addi-
tion to aerosol exposure, dermal exposures
around the patient’s glove area reportedly
resulted in skin sores. In late 1993, the
patient experienced a rapid 1- to 2-month
deterioration, with symptoms consistent with
what is termed descriptively an organic-
affective syndrome or toxic encephalopathy.
Mood lability, poor work performance, trou-
ble reading and doing scientiﬁc work, disori-
entation while driving, and dermal sores on
his extremities led to realization by family and
colleagues that he was medically ill. The
patient had reduced insight, but the severity
of symptoms led to medical examination of
the patient by his primary care physician and
a recommendation for immediate cessation of
exposure and medical leave from work.
Screening laboratory tests were normal except
for mildly elevated liver enzymes [aspartate
aminotransferase (AST), alanine aminotrans-
ferase (ALT)] less than 2 times the upper nor-
mal range. Signs and symptoms began to
improve rapidly in the days following
cessation of exposure. 
Initial Examination
The patient was referred for neurological
evaluation in December 1993, roughly
2 weeks after exposure cessation and while
still recovering. The following section out-
lines ﬁndings from the comprehensive physi-
cal and neurological examinations completed
at that time.
Subjective Complaints
The patient presented with numerous
complaints, many of which suggested
changes in neurocognitive abilities. The
reported symptoms included recent memory
impairment, declined word-finding and
reading skills, spatial disorientation, rage
and emotional lability, headaches, skin sores
and poorly healing infections, and auto-
nomic symptoms involving perceived and
measured changes in pulse, blood pressure,
and temperature (hyperautonomic).
Physical Exam
The patient was alert and cooperative and
had normal vital signs. General physical
examination was normal except for some
healing 2- to 4-week-old skin sores roughly
2–4 mm in size on the wrist and dorsum of
the hand, with the appearance of excoriated
eczematous dermatitis. Slight hyperhidrosis
was present in the palms.
Neurological Exam
The patient’s neurological examination was
mostly normal. Gait, cranial nerves, motor
function, coordination, sensory function, and
reflexes were all within normal limits.
However, observations of mental status were
notable for hesitant speech, decreased ﬂuency,
and psychomotor slowing.
Because of these neurological ﬁndings, the
patient was referred for comprehensive neu-
ropsychological evaluation and urgent labora-
tory studies. Because of adequate functioning
and observed improvement and no indication
of the nature of the putative toxins, the
patient was not hospitalized and no medical
intervention was taken.
Laboratory and medical findings.
Bloodwork revealed normal screening labs,
including complete blood count and routine
chemistries, with the exception of low serum
phosphorus and slightly elevated liver func-
tion (AST, ALT) tests, which resolved by
the second visit 1 week later. Other ancillary
tests were also well within normal limits,
including urinalysis, TmPO4 (renal thresh-
old phosphate excretion) for renal threshold
for phosphate excretion, and plasma and
urine amino acids. Skin biopsy revealed
nonspecific changes with microhemorrhage
and infiltrate without marked eosinophilia,
consistent with secondary infection and
eczematous dermatitis.
Neurophysiological findings. Electro-
myography-nerve conduction studies were
normal, as were visual and brainstem evoked
potential studies. Sleep-deprived electro-
encephalography was also entirely within
normal limits. 
Neuroimaging findings. Magnetic
resonance imaging studies revealed a slight
asymmetry of the hippocampi, with the left
hippocampus having minimally increased T2
signal intensity compared to right. In con-
trast, fluorodeoxyglucose positron emissions
tomography scan findings were normal
without any cortical or subcortical areas of
increased or decreased glucose utilization in
the basal state. 
Neuropsychological Evaluation
Clinical neuropsychology allows for the esti-
mation of CNS integrity through the mea-
surement of cognitive skills. Central to its
practice is the administration of standard-
ized, objective tests. Healthy normative
group data allow for control of variables
known to influence cognition, such as age
and education. A comprehensive clinical
examination involves assessment of multiple
cognitive domains, including intellect,
higher-order executive skills such as reason-
ing and cognitive flexibility, learning and
memory, language, visual-spatial skills, fine
motor skills, and mood. The resulting scores
are then examined relative to standardization
group norms. The pattern of performance is
also considered in light of the individual’s
estimated premorbid levels of functioning
based on demographics and scores that are
less susceptible to decline, even in the con-
text of neurological illness. The patient’s raw
scores were converted to standard scores,
with a mean of 100 and standard deviation
of 15. Figure 1 illustrates select scores repre-
sentative of performance in each neurocog-
nitive domain. For this individual,
premorbid level of functioning was esti-
mated to be well above average. Whereas for
an average individual a score of 70 (two
standard deviations below the mean) would
indicate impairment, for a person previously
estimated to have above-average and supe-
rior skills, an average score of 100 could be
clinically relevant and arouses concern for
decreased function. The results revealed a
constellation of ﬁndings indicating a decline
in functioning in speciﬁc areas. 
•H igher-order executive abilities (blue
bars: Trail Making Test, Wisconsin Card
Sorting Test, Arithmetic subtest – Boston
Figure 1. Initial neuropsychological evaluation test scores. JOLO, Benton Judgment of Line Orientation Test; WCST,
Wisconsin Card Sorting Test. 
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Diagnostic Aphasia Examination were
highly variable. While performance on a
test of concept formation requiring the
patient to attain, maintain, and shift
problem-solving strategies in response to
feedback was within normal limits, per-
formance on tasks involving sequencing
and cognitive flexibility suggested
decreased efﬁciency, and arithmetic skills
were markedly impaired. 
•L earning and memory skills (red bars:
Wechsler Memory Scale-Revised Visual
Learning, Verbal Learning, and Delayed
Memory Indices) were profoundly
impaired. Verbal learning was dispropor-
tionately affected relative to nonverbal
learning skills. Delayed recall skills indi-
cated minimal retention of information
over time, with scores suggesting a mem-
ory deficit of amnestic proportions (i.e.,
below the first percentile relative to age-
matched peers). 
• Although language abilities (pink bars:
Abbreviated Boston Naming Test,
Chapman-Cook Speed of Reading Test,
Controlled Oral Word Association Test–
Multilingual Aphasia Examination) were
variable, a marked reading deﬁcit was evi-
dent. In addition, verbal ﬂuency was also
below expectation, although this perfor-
mance may have been related to executive
dysfunction. 
• Visual–spatial skills (green bars; Benton
Judgment of Line Orientation Test,
Benton Facial Recognition Test) also were
variable, again with skills more closely
related to executive abilities being affected
to a greater degree. 
• Fine motor (orange bar: Finger Tapping
Test) skills were also impaired. 
• Although emotional distress was
reported, objective findings suggested
that the patient’s affective status (light
blue bar: Minnesota Multiphasic
Personality Inventory) did not account
for the neurocognitive findings at the
time of evaluation. 
Initial Diagnostic Impression
The initial neuropsychological examination
confirmed and documented the clinical
impression of an organic amnestic syndrome.
Findings were notable for a memory deﬁcit of
amnestic proportions, impaired auditory
attention, slowed calculation skills, and a mild
alexia. This constellation of findings con-
formed to what is often observed in illnesses
involving frontal–temporal structures and
related systems, and in this particular case the
pattern of deficits suggested possible dispro-
portionate involvement of the left hemisphere.
In addition to clear evidence of cognitive
dysfunction, multisystem involvement was
suspected on the basis of the history of skin
lesions, as well as possible renal, liver, and
autonomic nervous system findings on the
basis of history and laboratory tests.
Differential diagnostic considerations favored
the possibility of occupational laboratory
exposure to P. piscicida cultures as the envi-
ronmental cause of the syndrome given the
following: absence of other explanatory con-
ditions, temporal relation between increased
exposures and symptom onset, temporal rela-
tion between exposure cessation and symp-
tom resolution, and parallel between degree
of exposure and symptom magnitude.
Excluded by the clinical course and labora-
tory ﬁndings were alternative diagnoses such
as ischemic injury, epilepsy or seizure disor-
der, transient global amnesia, demyelinating
disease, other toxic encephalopathy, infection,
systemic metabolic disease, and indirect CNS
effects of pancreatic, hepatic, or renal injury.
The overall presentation suggested a cumula-
tive effect of chronic exposures with acute
decompensation throughout the fall of 1993
during increased exposure intensity. Although
clinical encephalopathy was clearly present,
the case did not permit an understanding of
whether this represented direct or indirect
effects of systemic exposure or any specific
understanding of the nature of putative
toxin(s). Excitotoxic mechanisms were con-
sidered (such as domoic acidlike agents), as
that would have clinical implications, but
were not supported by the clinical course and
laboratory ﬁndings. The exposures (primarily
dermal and inhalational) suggested a
lipophilic or amphiphilic agent with possible
long-term accumulation in body-fat stores,
lipid-rich organs (e.g., brain) or other viscera.
Unfortunately, no frozen fat or other tissue
biopsies were taken except for a serum sample
kept frozen. 
Longitudinal Course 
Diagnostic Impression at Six-Week
Follow-up
All contact with Pfiesteria was terminated
with acute illness. Although all laboratory
contact with toxic Pﬁesteria was avoided, the
patient remained in the aquatic biology ﬁeld.
The results of comprehensive reevaluation
after 6 weeks suggested resolution of previ-
ously observed deﬁcits, with mild neurocog-
nitive residuals. Figure 2 is a comparison of
follow-up and initial ﬁndings on select scores.
Although practice effects could contribute to
the observed improvement, they did not
account for them. The magnitude of gains
was such that marked recovery was indicated. 
Potential Long-Term Sequelae
The patient was instructed to exclude further
exposures to Pfiesteria and resumed work in
the research laboratory. Mild symptoms
reported in the months following exposure
were fatigue with exercise (previously well-
conditioned individual) and occasions of
slight disorientation when painting using latex
paints at home. Although premorbid tests
were not available, the patient self-reported
being an excellent reader (>1,000 words/min)
prior to exposure. Thus, the improved reading
score at follow-up likely reﬂected a continued
deﬁcit relative to estimated premorbid levels
of functioning. Nonetheless, the patient
returned to full, successful, and gainful
employment as a research scientist.
In 1999, 6 years after exposure, the
patient experienced a subacute episode of
visual disturbance and pain of the right eye
that resulted in inpatient admission to the
Neurology Service at Duke University
Medical Center. The age of the patient and
nature of the presentation suggested demyeli-
nating disease. Examination revealed a signiﬁ-
cant scotoma with essentially right temporal
hemianopsia, without other neurological
abnormalities. Visual evoked potential study
demonstrated abnormal conduction times
over the anterior visual pathway on the right,
but normal brainstem and somatosensory
evoked potentials. Cerebrospinal ﬂuid (CSF)
studies, contrast and noncontrasted MRI, and
neuropsychological evaluation were all within
normal limits. In particular, there was no
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Figure 2. Initial and 6-week follow-up neuropsychological test scores.
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imaging correlate to the lesion in the right
anterior (prechiasmatic) optic pathway or
elsewhere to support multiple demyelinating
lesions. CSF studies were negative for oligo-
clonal bands and revealed a normal IgG
index. Thus, a diagnosis of multiple sclerosis
was not supported. Steroid treatment was ini-
tiated, with resolution of many of the symp-
toms, and a second course was performed a
few weeks later for a brief recurrence of symp-
toms. Signiﬁcant visual deﬁcit remains in the
right eye, but there have been no further neu-
rological episodes. 
The relationship of this episode to the
original exposure remains unclear. At this
time, social and occupational functioning
remains within normal limits. There is no
evidence of neurological or cognitive dysfunc-
tion or other physical decline. The patient
remains actively employed and successful as a
research scientist.
Discussion
The case presented here offers compelling
evidence of transient neuropsychological
deﬁcits following prolonged, intense occupa-
tional laboratory exposure to P. piscicida cul-
tures. In this speciﬁc case, there exists a relative
certitude of the relationship of exposure to
Pﬁesteria cultures to the initially documented
health effects. Further, the constellation of
findings was consistent with that often
observed as a result of neurotoxin exposures,
with the implication of direct or indirect
frontal–temporal system involvement. The
marked neurocognitive deﬁcits largely resolved
within 6 weeks of exposure cessation, with
only minimal residual. Although the develop-
ment of neurological symptoms 9 years after
exposure cessation is intriguing, it is of course
less compelling with regard to causation, given
the lack of temporal relatedness to exposure.
Nonetheless, these symptoms raise the ques-
tion of long-term sequelae or vulnerability to
other illnesses, and these potential long-term
exposure effects of Pfiesteria are an area also
presently under investigation. 
Numerous other occupational laboratory
and civilian cases have presented to the MDC
of the Bryan ADRC for examination since
this initial case. Table 1 is a summary of some
of the findings of this small clinical series.
The clinical variation across cases is note-
worthy, particularly in the laboratory expo-
sure cases where there was known and proven
exposure to Pfiesteria cultures. There were
often secondary or preexisting medical condi-
tions that are commonly encountered in the
general population. These included reactive
airway disease and sinusitis, obstructive sleep
apnea, and chronic fatigue. Such complicat-
ing medical conditions were also present in
the civilian cases. The possibility of uncon-
scious modeling existed in nearly all cases
after the first two affected laboratory expo-
sures, given the high publicity of Pﬁesteria in
the lay and scientific press. Finally, possible
malingering or secondary gain (e.g., atten-
tion, secondary gain) certainly could be a fac-
tor and was a leading suspicion in the
symptomatology of one occupational civilian
case despite a convincing account of initial
exposures. The presence of confounding
medical illness, the exclusion or accounting
for other toxic exposures (e.g., alcohol or
drug), the presence of confounding psychi-
atric factors or illness, and clinical variability
are all commonly encountered in the evalua-
tion of toxic exposure cases and do not pre-
clude an added effect due to the putative
environmental agent. This situation suggests
that well-designed prospective epidemiologi-
cal investigation will be necessary to clearly
delineate Pfiesteria neurotoxic effects. Other
marine-associated illness and other adverse
health properties of estuarine waters must be
considered and carefully accounted for.
Further contributions to this variation
likely include possible differences in toxin(s)
(e.g., Pfiesteria subspecies and life cycles) as
well as differences in exposure route, intensity,
and duration. Molecular targets and target
organs and tissues have yet to be delineated as
well as the process of toxin(s) metabolism,
storage, and excretion. Downstream effects of
toxin(s) on tissue integrity, nuclear or mito-
chondrial integrity, or endogenous protein
targets are also possible. The possible priming
mechanism of repeated or long-term expo-
sures is unclear. The distinct possibility of sen-
sitization to antigens associated with Pﬁesteria
and/or its toxins should be considered given
the repeated exposures, and neuroimmune
mechanisms might account for some or all of
the acute or chronic health effects. In no
known human laboratory case has it been
shown that a ﬁrst-time, single-pulse exposure
to Pﬁesteria organism or toxin(s) has resulted
in health effects. The biological exceptions to
this would presumably be the acute stunning
and killing of ﬁsh by Pﬁesteria exposure and
reports of civilian case illness. However, the
mechanism of fish killing and the putative
toxin(s) involved may or may not be related to
mechanisms of human health effects.
The current cases do not clarify whether
the CNS effects are primary or secondary
results of the clear-cut systemic exposure
(inhalational and dermal) and systemic signs
(skin lesions, possible liver or renal dysfunc-
tion). Of course, host factors must also be
considered, as each individual also embodies
potentially predisposing genetic, medical
(e.g., host immune mechanisms), psychiatric,
and environmental factors that also likely
inﬂuence outcome.
Naturally, efﬁcient and systematic investi-
gation of these factors relies on identiﬁcation
of a biomarker. Until such time, full elucida-
tion of Pﬁesteria health effects will be greatly
hindered. Although public education is criti-
cal, scientific progress would be greatly
assisted if dissemination of information about
the potential human health effects of expo-
sure could proceed in an orderly and orga-
nized manner that discourages symptom
exaggeration and reassured the general public
through accurate accounts of Pfiesteria
research findings. Personal and external
sources of bias must be eliminated to the
extent feasible. 
Despite the considerable present ambiguity
surrounding Pﬁesteria and its exposure seque-
lae, the evidence of potential health effects
suggested by complaints (7), objective clinical
cases, and various published case series indi-
cate that use of precautionary measures and
thorough examination of exposed persons is
warranted. Evaluation of persons with alleged
exposures to P. piscicida should ideally
involve a thorough, rapid assessment. As
Grattan has noted, all suspect cases should be
considered and evaluated seriously and thor-
oughly (8). Because of the variation in symp-
tom development and manifestations, a
multidisciplinary approach involving internal
medicine, neurology, neuropsychology, and
occupational health will likely yield the most
productive data. Toward this end, storage of
acute and convalescent plasma and serum
samples, skin biopsies, fat biopsies, and bile
samples would also be ideal in anticipation of
Table 1. Signs and symptoms of laboratory- and environment-exposed cases.
Laboratory cases Environmental cases
1 2345 1 2 3 4
Physical complaints Y Y Y Y Y Y Y Y Y
Memory complaints N Y Y Y Y Y Y Y N
Mood/personality changes N Y Y Y Y N Y N Y
Abnormal neurological  Y Y N N Y – Y Y N
Abnormal physical exam (skin) N Y N N N Y N N Y
Abnormal neuroimaging/labs  N Y N N Y – N Y N
Confounding medical factors N N Y N Y – Y Y Y
Confounding psychiatric factors N N Y N Y Y Y N Y
Possible exposure effects Y Y ? ? ? – – – –
Potential modeling N N Y Y Y N Y N Y
Possible EAS – – – – – Y ? ? ?
Abbreviations: N, no; Y, yes; –, not applicable; ?, equivocal.Laboratory exposures to Pﬁesteria piscicida
the development of biomarkers or specific
assays for toxin(s). These could be used for
surrogate markers (e.g., inflammatory
cytokines, chemokines) that might index
exposure. The differential diagnosis is clearly
affected by the age and health status of the
person. Exclusion of competing etiologies
such as psychiatric illness, alcohol or drug
abuse, dementia or neurodegenerative illness,
small vessel cerebrovascular disease, and other
toxic causes is critical to narrow the spectrum
of symptoms associated with exposure. In
addition, study of those many persons with
known or suspected concomitant illnesses is
also essential, as they may be at greater risk
for developing illness as a result of exposure. 
Management should promote exposure
cessation and close medical follow-up by pri-
mary care and relevant specialists. Findings
from the case presented here and the series
followed in Maryland (3) suggest resolution
of symptoms in cases of acute exposure.
However, the symptom duration and long-
term effects in cases of low-level chronic
exposure remain unknown. Variations in
exposure route, intensity, and duration as
well as the previously noted factors possibly
contributing to presentation variability likely
affect the rate of resolution of illness as well. 
The Centers for Disease Control has put
forth criteria for possible estuary associated
syndrome (PEAS) (9). At present, a diagnosis
of PEAS requires that a healthcare provider
has ruled out other competing causes for
symptoms. We propose an expansion of this
classiﬁcation system of estuary associated syn-
drome (EAS) to allow for varying degrees of
certainty. Specifically, following numerous
examples of other illness and disease states
(e.g., Alzheimer’s disease) (10), discriminating
between possible, probable, and deﬁnite EAS
would enhance the sophistication of the
clinical designation and allow for the presence
of other contributing factors. Probable EAS
would require the absence of competing fac-
tors, proved exposure to Pﬁesteria organisms
or associated fish kills, and adherence to a
defined set of clinical symptoms including
neurocognitive symptoms and signs. Of
course, a diagnosis of definite EAS awaits
identification of a reliable, validated bio-
marker. However, differentiation between
possible and probable EAS could be made on
the bases of symptom constellations, tempo-
ral relationship to exposure, and presence or
absence of competing diagnoses. Further,
identification of laboratory versus environ-
mental cases may also aid rapid and clear
communication of information, particularly
given that occupational laboratory exposure
cases may differ radically from putative ongo-
ing occupational civilian (e.g., workers in
estuarine environments) or civilian exposures.
In summary, we present a case involving
the most prolonged and intense human expo-
sure to P. piscicida cultures known, with sig-
nificant associated neurological illness and
subsequent symptom resolution. Recurrence
of signiﬁcant neurological illness 6 years after
the exposure may represent a directly associ-
ated long-term effect despite cessation of
exposures, an increased vulnerability to other
diseases of the nervous system, or be totally
unrelated. As this second illness was not
proved to be multiple sclerosis (the most
likely diagnosis given the presentation) and
no other cause was identiﬁed, it was consid-
ered more likely than not to be related to the
initial occupational laboratory exposure. On a
scientiﬁc basis, we cautiously assert a probable
causative link between this known massive
exposure and the associated primary initial
illness and a possible causative or contributory
link to the secondary delayed illness, and look
forward to the biological and physiological
scientiﬁc progress that will facilitate rigorous,
systematic research of human health sequelae.
In the interim, we are convinced of the need to
be diplomatically responsive to public health
concern, to collect data to the extent feasible,
and to provide maximal clinical care to those
seeking medical assistance. 
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